<SEC-DOCUMENT>0001157523-23-001404.txt : 20230908
<SEC-HEADER>0001157523-23-001404.hdr.sgml : 20230908
<ACCEPTANCE-DATETIME>20230908083028
ACCESSION NUMBER:		0001157523-23-001404
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230908
FILED AS OF DATE:		20230908
DATE AS OF CHANGE:		20230908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		231243726

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53550988.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <div>&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div style="font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: center;">For the month of September 2023</div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
    <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div><br>
    </div>
    <div style="text-align: center;">Form 20-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> &#160; &#160; Form 40-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z239661d20baa45d9be0e61456ea1b3a9">

        <tr>
          <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div><a href="a53550988ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 1.54%; vertical-align: bottom;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom;">
            <div style="text-align: justify;"><a href="a53550988ex99_1.htm">Press Release dated September 8, 2023</a>.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center;">&#160;</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb6add5922af9451d85014a8922e6e283">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>Date: September 8, 2023</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-style: italic;">/s/ Brad McConn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div>Brad McConn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div>Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53550988ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z14f19653251246e4ab5c1f84a877aea1">

      <tr>
        <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> <i>The Company to host an earnings conference call via webcast</i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--September 8, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the &#8220;Company&#8221; or &#8220;IPA&#8221;) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a
            conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the
            call. </p>
          <p> ImmunoPrecise management will host the conference call followed by a question-and-answer period. </p>
          <p> <b>Conference Call:</b> </p>
          <p> Date: Thursday, September 14, 2023 <br>
            Time: 10:30 am Eastern time </p>
          <p> Participant Info: </p>
          <p> Conference ID: 9236374 <br>
            Participant Toll-Free Dial-In Number: 1 (888) 550-5658 <br>
            Participant Toll Dial-In Number: 1 (646) 960-0289 </p>
          <p> Attendee URL: https://events.q4inc.com/attendee/997889510 </p>
          <p> The conference call will be webcast live and available for replay via a link provided in the Events section of the company&#8217;s IR pages at https://www.immunoprecise.com/investors. </p>
          <p> Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. </p>
          <p> Anyone listening to the call is encouraged to read the company's periodic reports available on the company&#8217;s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and
            financial condition in those reports. </p>
          <div> </div>
          <p> <b>ImmunoPrecise Antibodies Ltd.</b> </p>
          <p> ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
            (collectively, the &#8220;IPA Family&#8221;). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in
            bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics
            against the most challenging targets. For further information, visit www.ipatherapeutics.com. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investor contact: investors@immunoprecise.com</b> </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
